GlassScriptPhysician profile
Darol D Joseff
NPI 1669554739
$37,178.38
in general payments reported to CMS, 2019-2025
24 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $126 · 2021: $26K · 2022: $5,868 · 2023: $1,397 · 2024: $1,549 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,775 · Education: $69.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,774.88 |
| Education | $69.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30,868.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,664.20 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $717.68 | 2021-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $696.97 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $603.31 | 2019-2025 | Krystexxa, Tavneos |
| Alexion Pharmaceuticals, INC. | $347.56 | 2019-2025 | Ultomiris |
| Akebia Therapeutics INC | $291.85 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $277.34 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.88 | 2022-2025 | Jardiance |
| Horizon Therapeutics Plc | $191.88 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $153.45 | 2020-2024 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $150.77 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $138.83 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $137.88 | 2023-2025 | Terlivaz, Acthar |
| Calliditas Therapeutics US INC. | $122.92 | 2022-2025 | Tarpeyo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $109.15 | 2019-2025 | |
| Novo Nordisk INC | $99.96 | 2022-2025 | Ozempic |
| Fresenius USA Marketing, INC. | $86.60 | 2025 | 2008t Bluestar Hemodialysis Machine |
| Pfizer INC. | $71.65 | 2023-2024 | |
| Ardelyx, INC. | $66.15 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $64.49 | 2022-2024 | Amvuttra, Onpattro |
| Mozarc Medical US LLC | $29.44 | 2024 | Palindrome |
| Xeris Pharmaceuticals, INC. | $22.40 | 2025 | Keveyis |
| Nxstage Medical, INC. | $20.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darol Joseff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.